Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of oral MT-1303 in relapsing-remitting multiple sclerosis
2012-002470-31Phase 2Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of amiselimod in relapsing-remitting multiple sclerosis (RRMS) (4 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoint: Total number of monthly MRI gadolinium-enhanced T1-weighted lesions across post-baseline visits. Started Sep 2012; status: completed.
02
Drugs
amiselimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2012-002470-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002470-31.